LAVA Therapeutics N.V. Ordinary Shares (LVTX)
LAVA Therapeutics N.V. is a biotech company focused on developing innovative immuno-oncology therapies. Specializing in gamma delta T cell engagers, LAVA aims to harness the immune system to target and destroy cancer cells. The company operates in the Netherlands and is dedicated to advancing treatments for various solid tumors.
Company News
XOMA Royalty and LAVA Therapeutics amended their share purchase agreement, reducing the initial cash amount per share to $1.04 and introducing a contingent value right (CVR). The tender offer has been extended to November 12, 2025, with the acquisition expected to close in Q4 2025.
XOMA Royalty Corporation has extended its tender offer to purchase LAVA Therapeutics shares until October 17, 2025, with a cash payment and contingent value right per share. The proposed acquisition is expected to close in Q4 2025, subject to customary closing conditions.
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -125% and 5.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Which penny stocks are you watching right now? The post Top Penny Stocks to Buy Now? 3 to Watch as September Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.